Intravenous autologous bone marrow mononuclear cell transplantation for cerebral embolism

Phase 1

• Conditions: cerebral embolism

• Registration Number: JPRN-UMIN000001133
• Lead Sponsor: ational Cerbral and Cardiovascular Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-05-01
• Study Completion: 2013-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient with cerebral hemorrhage or symptomatic hemorrhagic infarction. 2. Patient who expects brain surgery. 3. Patient with acute myocardial infarction. 4. Patient with coagulation disorder. 5. Number of Platelet < 100000/mm3 6. Serum creatinine level >2.0mg/dl 7. Patient with malignancy. 8. Patient with uncontrolled proliferative diabetic retinopathy. 9. Patient suspected infective endocarditis. 10. HBV, HCV, HIV or HTLV positive.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Improvement of NIHSS (before vs 1 month after cell transplantation) 2. Frequency of change for the worse in NIHSS (before vs 1 month after cell transplantation)

Secondary Outcome Measures

Name	Time	Method
1. mRS (1, 3 and 6 months after cell transplantation) 2. Barthel Index (1, 3 and 6 months after cell transplantation) 3. NIHSS (1, 3 and 6 months after cell transplantation) 4. Ratio of mRS=0, 1, 2 or 3 at discharge 5. Frequency of hemorrhagic infarction (1 and 6 months after cell transplantation) 6. Frequency of death at discharge